Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

• Appearance:while to off-while powder(Results:White powder)
• Identification: HPLC retention time(Results:Conforms)
• Melting Point: 42 ºC -45°C(Results:42°C-44°C)
• Specific optical rotation: -31.0°~-41.0°(Results:-36.0°
  )
• Purity by HPLC: no less than 98.0%(Results:-98.5%)
• Total impurity: no more than 2.0%(Results:-1.6%)
• Max Individual impurity: -no more than 0.5% (Results:-0.3%
  )
• Water content%(K&F): no more than 0.5% (Results:-0.1%
  )
• Residual solvents: EtOH no more than 0.5% (Results:-N.D)
  EtAC no more than 0.5% (Results:-N.D)
  n-Heptane no more than 0.5% (Results:-less than 0.1%)
• Residue on ignition : -less than 0.2%(Results:-0.10%)
• Heavy metals as Pb : no more than 20ppm(Results:-less than20ppm)
• Assay (HPLC): -no less than 98.0%(Results:-98.60%)
• Conclusion: Meets the Requirements